JPMORGAN upgrades ROCHE HOLDINGS AG to 'Underweight'

NEW YORK (dpa-AFX Analyst) - US bank JPMorgan raised its price target for Roche from 220 to 230 Swiss francs, but maintained its rating at "underweight." In response to the second-quarter figures, it slightly raised its sales and earnings forecasts for 2025, Richard Vosser wrote in a study released Monday. However, since the next active ingredients currently under development by the pharmaceutical company are risky, the potential for longer-term forecast increases is limited./rob/edh/la Publication of the original study: July 27, 2025 / 8:05 p.m. / BST First distribution of the original study: July 28, 2025 / 12:15 a.m. / BST Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

ISIN: CH0012032048

Hensoldt, Renk & Rheinmetall expensive

Rheinmetall, Renk, and Hensoldt have dominated the arms boom of recent years, but these stocks are now fundamentally hopelessly overvalued. P/E ratios exceed 60, price-to-sales ratios exceed 4, and this in a politically fragile environment with shaky fiscal discipline. This can be expensive for late-entering investors. But there are alternatives that have so far flown under the radar: solidly valued, operationally strong, and with catch-up potential. In our free report, we show you which three arms companies still have potential and how you can profit from the second wave of the turning point without getting burned by overheated high-flyers. Get the latest report! Don't miss out on which stocks are particularly likely to benefit from the global arms buildup and download the free PDF now.

This exclusive offer is only valid for a limited time! So download it now!